Concepedia

Author

Hironaga Satake

Kobe City Medical Center General HospitalORCID

Also Known As

Akihito Tsuji, H Satake, H. Satake, HIRONAGA SATAKE, Hironaga Satake, Satake Hironaga

301

Publications

3.4K

Citations

24

H-Index

49

Concepts

All Affiliations

Kobe City Medical Center General HospitalNational Cancer Center Hospital EastKansai Medical UniversitySt. Marianna University School of MedicineOsaka National Hospital
HS

About

Hironaga Satake is an author at Kobe City Medical Center General Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

23

667

2

Health Sciences

7

7

105

3

Nursing

1

1

13

4

Biostatistics

1

1

21

5

Cell Biology

1

1

25

Hironaga Satake

×

52

Publications

3K

Citations

24

H-Index

YearCitations

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang,

JAMA Oncology

2020

1.1K

Sotorasib in <i>KRAS</i> p.G12C–Mutated Advanced Pancreatic Cancer

John H. Strickler, Hironaga Satake, Thomas J. George,

New England Journal of Medicine

2022

425

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi,

The Oncologist

2017

104

Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer

Manabu Muto, Hironaga Satake, Tomonori Yano,

Gastrointestinal Endoscopy

2011

98

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)

Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada,

European Journal of Cancer

2018

97

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study

Takatsugu Ogata, Hironaga Satake, Misato Ogata,

Oncotarget

2018

82

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma

Hironaga Satake, Makoto Tahara, Satoshi Mochizuki,

Cancer Chemotherapy and Pharmacology

2016

64

Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

Hironaga Satake, Takeshi Kato, Koji Oba,

The Oncologist

2020

61

A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208)

Shogo Kobayashi, Hiroaki Nagano, Akira Tomokuni,

Annals of Surgery

2018

58

Radial incision and cutting method for refractory stricture after nonsurgical treatment of esophageal cancer

Tomonori Yano, Yusuke Yoda, Hironaga Satake,

Endoscopy

2013

49

Page 1